NANOLUTE: A post market registry on SCB demonstrated that MagicTouch SCB is associated with reduced revascularization rates in patients with coronary in-stent restenosis (ISR) up to 3-year of follow-up.

In patients with recurrent ISR, implantation of new DES would result in a vessel with multiple metal layers (“onion skin” phenomena). These “frequent flyer” patients seem to be at high risk for additional recurrences. SCB might emerge as the treatment strategy in this setting.

Ad hoc, powered studies are an indispensable tool for assessing the preliminary results in the westerns world population.